Vancouver, British Columbia - TheNewswire - September 23, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (the “Company” or “Lexston”) is pleased to announce that the company’s scientific research and development division led by Chief Science Officer, Dr. Philippe Henry, has begun work on its tryptamine pipeline with an initial focus on 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) at its newly acquired Zenalytic Laboratories.
With confirmation from Health Canada’s Controlled Substances Directorate to proceed with characterization work on the target molecule, 5-MeO-DMT, Lexston’s scientists have moved ahead with its plans to develop methods for the identification and quantification of this target tryptamine. The Company has also successfully developed a High-Pressure Liquid Chromatography (HPLC) assay for the determination and purity of 5-MeO-DMT, thus paving the way for future product development activities. Additionally, it has successfully collected Near-Infrared spectra (NIRs) from the purified substance to develop a portable rapid technique for the identification and quantification of tryptamine formulations at the point-of-care.
The Company is exploring different naturally derived botanical sources of 5-MeO-DMT, the use of different solvents and delivery systems for a formulation of a sub-psychoactive dosage. Based on its neuro-vasocontraction abilities this formulation will be used in conjunction with clinical partners specifically targeted for the alternative treatment of migraines and cluster headaches.
In support of clinical applications, the Lexston team is also collecting serotonin and other receptor affinity data for 5-MeO-DMT, its metabolites and other closely related tryptamines. 5-MeO-DMT possesses unique pharmacodynamic and pharmacokinetic properties imparted by its specificity for serotonin receptors 5HT-1a,7,6,1d and dopamine D1. Unraveling the mechanism underlying the mode of action of this tryptamine is expected to shed light on potential novel treatments for major depressive disorders and addiction.
“We believe that the 5-MeO pathway is fundamental to the development of multiple novel treatments and the activation of a tryptamine production pipeline early in the upcoming psychedelic trend is vital to accelerating the access to treatment with these potentially life-altering compounds.” stated Graeme Staley, Director of Lexston.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant-derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
Lexston Life Sciences Corp.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company and its business within the meaning of applicable securities laws, including the business plans and prospects of the Company. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under its SEDAR profile at www.sedar.com.
Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.